Vous avez cherché: aspergillosis (Danois - Anglais)

-aspergillosis,
aspergillosis,

51 aspergillosis og raske forsøgspersoner.
undesirable effects reported in subjects receiving voriconazole

behandling - invasiv aspergillosis studie 0041
treatment - invasive aspergillosis study 0041

j02ax04 secondline treatment of invasive aspergillosis
j02ax04 secondline treatment of invasive aspergillosis

andel af patienter (%) med verificeret/sandsynlig aspergillosis
proportion (%) of patients with proven/probable aspergillosis

invasiv aspergillosis (en type svampeinfektion forårsaget af aspergillus sp.)
invasive aspergillosis (a type of fungal infection due to aspergillus sp),

patientandel (%) med bevist/ sandsynlig aspergillosis on- treatment periodeb 1899d 316e
proportion (%) of patients with proven/ probable aspergillosis on-treatment periodb 1899d 316e

af disse patienter havde 37 invasiv candidiasis, 10 havde invasiv aspergillosis og 1 patient havde candidiasis i øsofagus.
of these, 37 had invasive candidiasis, 10 had invasive aspergillosis, and 1 patient had esophageal candidiasis.

behandling af refraktære svampeinfektioner (invasiv aspergillosis, fusariosis, chromoblastomycosis/mycetoma, coccidioidomycosis)
treatment of refractory fungal infections (invasive aspergillosis, fusariosis, chromoblastomycosis/mycetoma, coccidioidomycosis)

undersøgelsen af vfend til behandling af invasiv aspergillosis omfattede 277 immunforsvarskompromitterede patienter (patienter, hvis immunsystem ikke fungerede korrekt).
the study of vfend in the treatment of invasive aspergillosis involved 277 immunocompromised patients (patients whose immune system was not working properly).

104 febrile patienter med neutropeni; 56 patienter med invasiv candidiasis; 1 patient med candidiasis i øsofagus; og 10 patienter med invasis aspergillosis.
104 febrile, neutropenic patients; 56 patients with invasive candidiasis; 1 patient with esophageal candidiasis; and 10 patients with invasive aspergillosis.

ved behandlingen af invasiv aspergillosis var andelen af patienter, der responderede på behandlingen, højere med vfend end med amphotericin b (53 % i forhold til 31 %).
in the treatment of invasive aspergillosis, the proportion of patients responding to treatment was higher with vfend than with amphotericin b (53% versus 31%).

databasen repræsenterer en heterogen population indeholdende patienter med maligne hæmatologiske sygdomme, hiv-inficerede patienter med øsofageal candidiasis og refraktære svampeinfektioner, non-neutropene patienter med candidæmi eller aspergillosis og raske forsøgspersoner.
this represents a heterogeneous population, containing patients with haematological malignancy, hiv infected patients with oesophageal candidiasis and refractory fungal infections, non-neutropenic patients with candidaemia or aspergillosis and healthy volunteers.